Jaime Alberto Restrepo SotoMaría Isabel MéndezJonathan Berman2026-03-222026-03-22202110.4269/ajtmh.20-1510https://doi.org/10.4269/ajtmh.20-1510https://andeanlibrary.org/handle/123456789/59164Citaciones: 1We present case reports of two patients treated with miltefosine for mucocutaneous leishmaniasis whose gastrointestinal symptoms were initially diagnosed as a drug reaction and only later recognized as due to COVID-19. Gastrointestinal symptoms of COVID-19 are unusual, whereas gastrointestinal adverse drug reactions are very common. These reports exemplify that this infrequent presentation of COVID-19 is likely to be ascribed to a more common etiology such as a gastrointestinal drug reaction.enMiltefosineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMedicineDrugBetacoronavirusVirologyPharmacologyarticle